HHS & Healthcare Contracts Intelligence — April 29, 2026

Basilea Pharmaceutica International Ltd secured a $92,501,232 obligation (potential $267,582,260 including options) cost-sharing contract from HHS/BARDA on 2024-09-18 for antimicrobials R&D under NAICS 541714, with a 7-year base to 2031-09-30 and possible extension to 2035-12-31. This provides ~$13.2M annual revenue estimate on base obligation, bolstering long-term biotech funding in health preparedness.

R&D execution risks on Basilea Pharmaceutica International Ltd's $92.5M HHS/BARDA contract for antimicrobials, with cost-sharing structure and only $36.2M outlayed to date against milestones to 2031-09-30.

Unexercised options limit realization of $267.6M ceiling on Basilea Pharmaceutica International Ltd's HHS/BARDA award, with annual revenue potentially dropping below $13.2M if options lapse.

Basilea Pharmaceutica International Ltd's $92.5M HHS/BARDA contract offers expansion to $267.6M via options for antimicrobials R&D in resistant infections.

HHS/BARDA's $92.5M obligation (ceiling $267.6M) to Basilea Pharmaceutica International Ltd under full open competition underscores investment in biotech R&D (NAICS 541714, PSC AN42) for fungal/bacterial threats, with 7+ year duration.

{"entity"=>"Basilea Pharmaceutica International Ltd", "reason"=>"$92.5M HHS/BARDA obligation with $267.6M ceiling; track outlay beyond $36.2M", "trigger"=>"outlay progress beyond $36.2M"}

{"entity"=>"Basilea Pharmaceutica International Ltd", "reason"=>"Long-term R&D milestones on $92.5M contract", "trigger"=>"performance milestones to 2031-09-30 or option exercises to 2035-12-31"}